PDCD1 and metastatic melanoma: Similarly, a study including patients with NSCLC, renal cell carcinoma and metastatic melanoma treated with anti PD-1 immunotherapy demonstrated improved progression-free survival (PFS) and overall survival (OS) in patients who developed thyroid dysfunction compared to patients without (22).